Thursday, October 15, 2026
ExploreSearch
Via News
Via News Knowledge File

Chevron Corporation

organization80% conf.·synced Oct 15, 2026

Integrated energy company with upstream and downstream operations globally, stock ticker CVX

60
sourced metrics
611
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Return Ytd
42.4%
Oct 14, 2026reference only
Price 52 Week High
222.04USD
Oct 14, 2026reference only
Stock Price
222.04USD
Oct 14, 2026reference only
Market Cap
438700253679USD
Oct 14, 2026reference only
Price 52 Week Low
146.75USD
Oct 14, 2026reference only
Revenue
70055000000.0USD
Jun 30, 2026reference only
Eps
6.11USD_per_share
Jun 30, 2026reference only
Shares Outstanding
1975771274.0shares
Jun 30, 2026reference only
Total Assets
330135000000.0USD
Jun 30, 2026reference only
Net Income
12072000000.0USD
Jun 30, 2026reference only
Cost Of Revenue
36607000000.0USD
Jun 30, 2026reference only
Total Liabilities
134577000000.0USD
Jun 30, 2026reference only
Stockholders Equity
189883000000.0USD
Jun 30, 2026reference only
Operating Cash Flow
2514000000.0USD
Mar 31, 2026reference only
Rd Expense
427000000.0USD
Dec 31, 2025reference only

Stated objectives

Reach 1M BOE/day production in Permian Basin

source
target: 1000000 BOE per day by 2025-12-31 00:00:00stated

Chevron plateau production target in the Bakken

source
target: 200,000 barrels oil equivalent per day stated

Projected full year revenue of $193.17 billion

source
target: 193.17 billion USD stated

Projected full year earnings of $8.05 per share

source
target: 8.05 USD per share stated

Grow free cash flow annually

source
target: 10% annual growth by 2030-01-01 00:00:00stated

Return capital to shareholders through dividends and buybacks

source
target: 10-20 billion USD annually by 2030-01-01 00:00:00stated

Investment opportunities in Venezuela

source
stated

Grow cash flow and earnings through highest-return capital investments

source
by 2026-12-31 00:00:00stated

U.S. production of more than two million barrels of oil equivalent per day

source
target: 2000000 by 2026-12-31 00:00:00stated

Lower the carbon intensity of operations

source
stated

Relationship graph · 611 connections

operates in
85
located in
77
Competes with
68
Covered by
54
Employs
52
acquired by
39
Owns
34
Invested in
29

Via News coverage

Global M&A Wave: Four Major Deals Across Food, Tech and Energy Mark Cross-Sector Acquisition Surge
March 3, 2026
Natural Gas Futures Is 18% Up In The Last 21 Sessions
October 9, 2024
Natural Gas Futures Bullish Momentum With A 18% Jump In The Last 21 Sessions
October 8, 2024
Palladium Futures Bearish Momentum With A 3% Slide In The Last 10 Sessions
October 8, 2024
Platinum Futures Went Down By Over 2% In The Last 5 Sessions
October 8, 2024
Copper Futures Is 2% Down In The Last 5 Sessions
October 8, 2024
PIMCO Dynamic Income Fund, John Hancock Hedged Equity & Income Fund, Another 3 Companies Have A High Estimated Dividend Yield
June 23, 2024
OFS Capital Corporation, Eaton Vance Senior Floating, Another 7 Companies Have A High Estimated Dividend Yield
June 11, 2024
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com